| Supplier |
Creative Peptides |
| Product # |
10-101-197 |
| Pricing |
Inquire
|
| LabelingTarget |
Somatostatin receptor
|
| Synonyms |
Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl]-d7; SOM 230-d7SOM 320-d7; Signifor-d7;
|
| MolecularFormula |
C₅₈H₅₉D₇N₁₀O₉
|
| MolecularWeight |
1054.25
|
| Sequence |
Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl]-d7
|
| Explanation |
Isotope labelled Pasireotide. Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor®, which is used in the treatment of Cushing's disease.
|
| Application |
Pasireotide-d7 is invesgated for the treatment of Cushing's disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
|
| Purity |
98.0 % min
|
| Functions |
Somatostatin receptor activity
|
| Organism |
Human
|